fludarabine + rituximab + VELCADE
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma
Conditions
Follicular Lymphoma
Trial Timeline
Sep 1, 2009 → Oct 1, 2011
NCT ID
NCT00850499About fludarabine + rituximab + VELCADE
fludarabine + rituximab + VELCADE is a phase 2 stage product being developed by Johnson & Johnson for Follicular Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00850499. Target conditions include Follicular Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00850499 | Phase 2 | Terminated |
Competing Products
20 competing products in Follicular Lymphoma